Navigation Links
InterMune to Present at Canaccord Adams Conference
Date:8/7/2008

BRISBANE, Calif., Aug. 7 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the Canaccord Adams 28th Annual Global Growth Conference in Boston on August 13, 2008 at 1:00 p.m. EDT.

To access a live audio webcast of the presentation, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. InterMune Reports Second Quarter 2008 Financial Results and Business Highlights
2. InterMune to Present at BMO Healthcare Conference
3. InterMune to Release Second Quarter 2008 Financial Results and Provide Business Update on July 31
4. InterMune to Present at Jefferies Healthcare Conference
5. InterMune to Present at Goldman Sachs Healthcare and Needham & Co. Biotechnology and Medical Technology Conferences
6. InterMune to Present at Citigroup Healthcare Conference
7. InterMune to Present at Bank of America Health Care Conference
8. InterMune to Present at Deutsche Bank Health Care Conference
9. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
10. Evotec Expands Collaboration With InterMune
11. InterMune to Present at the SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... F.E.E.D. Co., the Feline ... their revolutionary, veterinarian-designed product for indoor cats. The NoBowl Feeding System replaces the ... food the way nature intended. NoBowls make cats happy and healthy. , Since ...
(Date:4/29/2016)... CO (PRWEB) , ... April 29, 2016 , ... ... addressing the necessary fundamentals to transform technology into a viable company, CereScan’s CEO, ... growth. Mr. Kelley, a recognized leader and mentor in the Denver area ...
(Date:4/28/2016)... , April 28, 2016 ... reports the Company,s CEO  was featured in an ... Enter When VCs Fear To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... magazine is an essential business journal ... from emerging biotechs to Big Pharmas. Their content ...
(Date:4/27/2016)... , ... April 27, 2016 , ... Cambridge Semantics, ... semantic web technology, today announced that it has been named to The Silicon Review’s ... financial services and other markets, Cambridge Semantics serves the needs of end users facing ...
Breaking Biology Technology:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
Breaking Biology News(10 mins):